= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Exclusive License and Co-Funding Agreement • February 4th, 2021 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND CO-FUNDING AGREEMENT (this “Agreement”), entered into as of October 7, 2020 (the “Execution Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a company incorporated under the laws of the State of Delaware (“Takeda”), and Arrowhead Pharmaceuticals Inc., a company organized and existing under the Laws of the State of Delaware (“Arrowhead”). Arrowhead and Takeda are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND CO-FUNDING AGREEMENTExclusive License and Co-Funding Agreement • May 10th, 2022 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This First Amendment (this “First Amendment”), entered into as of March 15, 2022 but effective retroactively as of October 7, 2020 (the “First Amendment Effective Date”), is made to that certain Exclusive License and Co-Funding Agreement (the “Agreement”), dated as of October 7, 2020, by and between Takeda Pharmaceuticals U.S.A., Inc., a company incorporated under the laws of the State of Delaware (“Takeda”), and Arrowhead Pharmaceuticals Inc., a company organized and existing under the Laws of the State of Delaware (“Arrowhead”). The parties to this Agreement are collectively referred to as the “Parties” and individually as a “Party.” Capitalized terms used but not defined in this First Amendment have the meanings ascribed to them in the Agreement.
